tbuckley/cabot-search huggingface dataset:
The effect of increasing doses of pegfilgrastim (Peg) on thrombocytopenia (T) in breast cancer (BC) patients (pts) receiving taxotere (Doc), doxorubicin, cyclophosphamide (TAC) and plinabulin (Plin)
Authors: D.W. Blayney, I. Bondarenko, Y. Shi, S. Ogenstad, L. Du, L. Huang, R. Mohanlal
Journal: Annals of Oncology (2019)
Mutational profiling of tumour tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Authors: S. Yaung, C. Woestmann, L. Xi, C. Ju, B. Hinzmann, M. Thomas, F. Lasitschka, M. Meister, M. Schneider, F.J.F. Herth, T. Muley, B. Wehnl, J. Palma, X.M. Ma
Journal: Annals of Oncology (2019)
FRI0522 Early SLICC/ACR Damage Index in Adolescents with Systemic Lupus Erythematosus
Authors: L.F. Bogmat, N.S. Shevchenko, E.V. Matvienko
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Organs and systems damage on the early stage of Systemic Lupus Erythematosus (SLE) course (≤1.5 years from the disease onset) is an important prognostic factor in adolescents. So called "early damage" in this category of patients is commonly associated with higher mortality rate. <h3>Objectives</h3> To assess the early SLICC/ACR Damage Index (eSDI) in adolescents with SLE <h3>Methods</h3> This was a retrospective analysis of SLE cases in adolescents with ≤1.5 years from disease onset. SLE diagnosis was based on SLICC 2012 criteria. The "early damage" was defined as irreversible damage of organs and systems not related to the current active inflammatory process and which develops during the first 1.5 years of disease<sup>1,2</sup>. The eSDI calculation method was the same as for SLICC/ACR Damage Index. Descriptive statistics data are presented as mean ± SD. <h3>Results</h3> 20 cases (17 females) were included to the analyzis. The mean age at SLE onset was 168.05±23.5 months. The mean disease duration – 15.75±2.51 months. Patients with subacute disease onset (66.7%) and mild activity (52.4%) prevailed. The mean cumulative prednisone-adjusted daily GC-dose was 10.66±3.69 mg. 33.3% of patients didn9t have any early damage (eSDI =0). Early damage with eSDI from 1 to 4 points was found in 66.7% of cases, mainly due to eye impairments (72.7%). Retinopathy was the most frequent form of eye damage (92.3%), manifested as arterial constriction (91.7%) and venous dilatation (21.6%). Cataract was found in 1 patient. Muscular atrophy was found in 22.2% of patients with early damage. Avascular whirlbone necrosis reported in 5.65%. eSDI value correlated with disease activity. In patients on medicated remission (prednisone less than 10 mg/day; n=3) eSDI ranged from 0 to 1. In cases with I (n=12) and II (n=5) degrees of SLE activity eSDI was 1-2 points and 2-4 points accordingly <h3>Conclusions</h3> eSDI value ≤1 seems to be the most favorable for remission prediction in adolescents with SLE. eSDI ≥2 points could be considered as a factor of unfavorable outcome in this category of patients. <h3>References</h3> Rahman P. Et all., 2001 Adrianova I, Ivanova M, 2005 <h3>Disclosure of Interest</h3> None declared
Effects of dietary restriction in cancer patients receiving irinotecan
Authors: R.A.G. Van Eerden, F.M. de Man, G.M. van Doorn, E. Oomen-de Hoop, S.L. Koolen, J.F. Olieman, P. de Bruijn, J.N. Veraart, H.K. van Halteren, Y. Sandberg, A. Moelker, J.N.M. IJzermans, M.P. Lolkema, T. van Gelder, M.E.T. Dollé, R.W.F. de Bruin, R.H.J. Mathijssen
Journal: Annals of Oncology (2019)
Annals Graphic Medicine - A Step Toward Health
Authors: Jaffer Shah, Raida Shah
Journal: Annals of Internal Medicine (2019)

Web Exclusives15 October 2019Annals Graphic Medicine - A Step Toward HealthFREEJaffer Shah and Raida Shah, MDJaffer ShahSearch for more papers by this author and Raida Shah, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G18-0020 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: The authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G18-0020.Author/Illustrator Information: Jaffer Shah (e-mail, [email protected]el.edu); Raida Shah, MD (e-mail, [email protected]com).This article was published at Annals.org on 8 October 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 October 2019Volume 171, Issue 8Page: W46-W47KeywordsConflicts of interestDisclosureHealth care ePublished: 8 October 2019 Issue Published: 15 October 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study
Authors: B. Clémence, J. Taieb, M. Boulin, K Le Malicot, L.M. Dourthe, B. Avisse, P. Laplaige, C. Borel, D. Arsene, F. Kikolski, B. Denis, P. Geoffroy, R. Coriat, G. Piot, C. Lepage
Journal: Annals of Oncology (2019)
Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: A propensity score matching analysis from SEER database
Authors: J. Chen, Z. Wang, J. Zhao, S. Zhu, G. Sun, J. Liu, H. Zhang, X. Zhang, P. Shen, H. Zeng
Journal: Annals of Oncology (2019)
A metabolomic recurrence score for risk-stratification of elderly patients (pts) with early colorectal cancer (eCRC)
Authors: S Di Donato, A. Vignoli, E. Mori, L. Tenori, L. Malorni, S. Cantafio, G. Mottino, D. Becheri, A. Mccartney, C. Biagioni, F.l. De Monte, A Di Leo, C. Luchinat, L. Biganzoli
Journal: Annals of Oncology (2019)
BEWARE OF THE GLUE
Authors: R Romero-Castro, VA Jimenez-Garcia, P Hergueta-Delgado, F Argüelles-Arias, P Cordero-Ruiz, B Maldonado-Perez, ML Morales-Barroso, JL Caceres-Galan, F Pellicer-Bautista, A Caunedo-Alvarez
Journal: Endoscopy (2019)

Endoscopic injection of cyanoacrylate (CYA) was a stepforward in the therapy of gastric varices (GV). However has been associate to adverse events, mainly, GE (glue embolism). To minimize the risk of GE, EUS-guided injection in the perforating feeding vein of GV of CYA was reported (1), followed by the deployment of coils in GV without injection of CYA (2). Another approach is to deploy into the gastric varix itself one or two coils followed by injection of CYA (3, 4). One multicenter study reported a rate of pulmonary GE of 30% after an average injection of CYA mixed with lipiodol by EUS-guidance (5).
A phase I open-label, non-randomized study of recombinant super-compound interferon (rSIFN-co) in patients with advanced solid tumours
Authors: A. Seet, M.C.F. Macapagal, A. Ahmad, G. Li, M.L. Goh, M.C.H. Ng, T. Tan, D.S.W. Tan, S.P. Choo, W.T.D. Lim, D.W.M. Tai
Journal: Annals of Oncology (2019)
Abstract #2361: Development of a transgenic zebrafish system for oro-esophageal cancer research
Authors: Bo Hu, Chengjing Zhang, Kouwendy Baawo, Rong Qin, Ju-Ahng Lee, Xiaoxin (Luke) Chen
Journal: Cancer Research (2009)

The zebrafish has become a useful model organism for research on development and diseases. Recently it has been used for cancer research of several organ sites, including the gastrointestinal tract. However, there has been no zebrafish model system for studying oro-esophageal carcinogenesis. In the present study, we first characterized the histology of the upper gastrointestinal tract of zebrafish. We found that zebrafish tongue was covered by a non-keratinized stratified squamous epithelium, which was similar to the oro-esophageal epithelium in humans. Zebrafish esophagus was covered by a simple columnar epithelium containing mucous cells. In situ hybridization showed that keratin 5, which is expressed in the basal cell layer of mammalian oro-esophageal epithelium, was strongly expressed in all cell layers of the squamous epithelium of zebrafish tongue. A highly conserved promoter of zebrafish keratin 5 (zK5) was cloned to drive transgenic expression of green fluorescent protein (GFP). GFP was found to be strongly expressed in the periderm and the cornea. In adult fish, GFP was also abundantly expressed in the tongue and fin. GFP expression in transgenic fish recapitulated endogenous zK5 gene expression as shown by in situ hybridization. This study indicated a high fidelity of GFP reporter gene expression in the tongue under the control of zK5 promoter. This transgenic system may be used for future studies on oro-esophageal development and cancer.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2361.
Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations
Authors: T. Wróbel, E. Karnas, J. Catapano, M. Luty, K. Piwowarczyk, E. Zuba-Surma, D. Ryszawy, J. Czyż
Journal: Annals of Oncology (2019)
P11.39 Chloroquine as an anti-glioblastoma therapeutic: repurposing of an old drug
Authors: L Roy, M Poirier, D Fortin
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Glioblastoma (GBM) is the most common and aggressive type of primary brain tumour in adults. These tumours depict anarchic proliferation and brain infiltration as well as radio- and chemoresistant profiles. The complete surgical resection is unachievable and responses to standard therapy are transitory. Recurrence is thus inevitable and patient prognosis is generally less than 15 months. Transforming growth factor-beta (TGF-β) holds a substantial role in supporting the GBM phenotype. We showed that TGF-β 1 expression levels correlate with overall and progression-free survival in newly diagnosed GBM patient. We also observed that chloroquine (CQ) can reduce the production of TGF-β together with proliferation, invasion, radioresistance and radio-induced invasion in vitro. Unfortunately, little is known regarding the ability of CQ to penetrate the blood-brain barrier (BBB). Therefore, our objective is to determine whether intravenous (IV) or intra-arterial (IA) infusions of CQ and hydroxychloroquine (HCQ), a pharmacological analog of CQ, can yield therapeutic brain concentrations. MATERIAL AND METHODS To assess BBB penetration, the brain, plasma and cerebrospinal fluid (CSF) concentrations of CQ/HCQ were measured by LCMS/MS at different timepoints post-IV or post-IA infusions with 20 mg/kg of CQ/HCQ in tumour-free Wistar rat. For the survival studies, We implanted 10’000 F98 murin glioblastoma cells in the right putamen of Fischer rats. Ten days post-implantation, IA and IV infusion were accomplished through cannulations of the external right carotid and tail vein respectively. RESULTS With IV injections, CQ/HCQ brain concentrations 15 minutes post-injection reached 15.76 mg/g (0.18 µM) and 1.67 mg/g (0.078 µM) respectively. However, following IA infusions, we observed a 1.74 and 20.9 fold increase (20 mg/kg HCQ) as well as 7.1 and 84.7-fold-increase (20 mg/kg CQ) in contra- and ipsilateral brain concentrations respectively. Although brain concentrations gradually decreased over time post-IA infusions, the ipsilateral hemisphere CQ concentration was still 82.81 mg/g (34.52 µM) after 6 hours. Whereas plasma concentrations were very similar following IV and IA infusions, both molecules barely accumulated in the CSF and only when using IA infusions. The median survival of the control group (IA phosphate-buffered saline) and the group treated with 20 mg/kg CQ IV were 23.5 days and 24.5 days respectively. However, rats injected with 20 mg/kg CQ IA had a median survival of 28.5 days. CONCLUSION These results suggest that IA CQ could be used to abrogate the GBM phenotype. As TGF-β is associated with resistance to both radio- and chemotherapy, we plan to characterize the combination of IA infusions of CQ in combination with radiation or chemotherapy (carboplatin).
The head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients
Authors: R.G. Herrera Gomez, L. Mezquita, E. Auclin, L. Heraudet, M. Plana, S. Salas, V. Cristina, A. Garcia Castano, V. Arrazubi, J.J. Grau, K. Saleh, B. Cirauqui Cirauqui, R. Mesia Nin, C. Even, M. Taberna, A. Daste, S. Peters, B. Besse, N. Baste-Rotllan
Journal: Annals of Oncology (2019)
Triple MET/SRC/PIM inhibition in MET addicted tumors
Authors: I. Attili, L. Bonanno, J.P. Bracht, J. Berenguer, C. Codony-Servat, J. Codony-Servat, M. Ito, P.F. Conte, J.J. Cui, N. Karachaliou, R. Rosell
Journal: Annals of Oncology (2019)
Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
Authors: P. Tralongo, S. Bordonaro, G Di Lorenzo, N. Borsellino, G. Facchini, S. Rossetti, V. Martelli, V. Longo, A.C. Tralongo, F. Caspani, A. Tuzi, M. Spada, N. Calvani, P. Carlini, U.F.F. De Giorgi
Journal: Annals of Oncology (2019)
Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Authors: M.H. Voss, A.A. Azad, A.R. Hansen, J.E. Gray, S.J. Welsh, I. Achour, H. Hu, L. Lewis, F.L. Walcott, S.F. Oosting
Journal: Annals of Oncology (2019)
IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
Authors: E. Grande, M. Galsky, J.A. Arranz Arija, M. De Santis, I.D. Davis, U.F.F. De Giorgi, M. Mencinger, E. Kikuchi, X. Garcia del Muro, M. Gumus, M. Özgüroğlu, A. Rezazadeh Kalebasty, S.H. Park, B.Y. Alekseev, F.A.B. Schutz, J.-R. Li, A. Mecke, S. Mariathasan, A. Thastrom, A. Bamias
Journal: Annals of Oncology (2019)
Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Authors: N. Mach, G. Curigliano, A. Santoro, D.-W. Kim, D.W.M. Tai, S. Hodi, S. Wilgenhof, T. Doi, T. Longmire, H. Sun, A. Xyrafas, S. Gutzwiller, L. Manenti, C.-C. Lin
Journal: Annals of Oncology (2019)
Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality
Authors: Jeffrey A. Lieberman, Scott A. Small, Ragy R. Girgis
Journal: American Journal of Psychiatry (2019)

Scientific progress in understanding human disease can be measured by the effectiveness of its treatment. Antipsychotic drugs have been proven to alleviate acute psychotic symptoms and prevent their recurrence in schizophrenia, but the outcomes of most patients historically have been suboptimal. However, a series of findings in studies of first-episode schizophrenia patients transformed the psychiatric field’s thinking about the pathophysiology, course, and potential for disease-modifying effects of treatment. These include the relationship between the duration of untreated psychotic symptoms and outcome; the superior responses of first-episode patients to antipsychotics compared with patients with chronic illness, and the reduction in brain gray matter volume over the course of the illness. Studies of the effectiveness of early detection and intervention models of care have provided encouraging but inconclusive results in limiting the morbidity and modifying the course of illness. Nevertheless, first-episode psychosis studies have established an evidentiary basis for considering a team-based, coordinated specialty approach as the standard of care for treating early psychosis, which has led to their global proliferation. In contrast, while clinical high-risk research has developed an evidence-based care model for decreasing the burden of attenuated symptoms, no treatment has been shown to reduce risk or prevent the transition to syndromal psychosis. Moreover, the current diagnostic criteria for clinical high risk lack adequate specificity for clinical application. What limits our ability to realize the potential of early detection and intervention models of care are the lack of sensitive and specific diagnostic criteria for pre-syndromal schizophrenia, validated biomarkers, and proven therapeutic strategies. Future research requires methodologically rigorous studies in large patient samples, across multiple sites, that ideally are guided by scientifically credible pathophysiological theories for which there is compelling evidence. These caveats notwithstanding, we can reasonably expect future studies to build on the research of the past four decades to advance our knowledge and enable this game-changing model of care to become a reality.
A phase Ib/II study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with mXELOX as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Authors: J. Ji, L. Shen, Z. Li, X. Gao, J. Gong, D. Liu, X. Wu, S. Xu, X. Jin, B. Li, M. Wang, Y. Xia
Journal: Annals of Oncology (2019)
Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)
Authors: Y. Cheng, Q. Wang, K. Li, J. Shi, Y. Liu, L. Wu, B. Han, G. Chen, J. He, J. Wang, D. Lou, H. Yu, H. Qin, X.-L. Li
Journal: Annals of Oncology (2019)
High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial
Authors: Steven Le Gouill, Catherine Thieblemont, Emmanuel Gyan, Olivier Tournilhac, Guy Laurent, Gandhi Damaj, Roch Houot, Corinne Haioun, Remy Gressin, Alexandra Traverse-Glehen, Marie-christine Béné, Elisabeth Macintyre, marie-Hélène delfau-Larue, Bruno Lioure, Guillaume Cartron, Philippe Moreau, Herve Tilly, Sylvie caulet-Maugendre, Mary Callanan, Olivier Hermine
Journal: Blood (2010)
Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumour microenvironment of mesothelioma
Authors: C. Ballesteros-Merino, T. Herz, S.E. Church, M. Widmaier, A. Budco, D. Medrikova, I. Kanchev, A. Spitzmueller, A. Shaepe, A. White, J. Reeves, A.H. Sullivan, M. Bailey, S. Jensen, J. Handy, R. Sanborn, C. Bifulco, S. Warren, J.M. Beechem, B. Fox
Journal: Annals of Oncology (2019)
Assessing quality of life and experiences of diagnostic trajectories of sarcoma patients: The QUEST study protocol
Authors: V. Soomers, O. Husson, I.M.E. Desar, D. Strauss, R.L. Haas, K. Verhoef, M.A.J. van de Sande, L. Been, M.C. Parry, L.V. van de Poll-Franse, W.T. van der Graaf
Journal: Annals of Oncology (2019)
Safety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data
Authors: T. Decaens, B.-Y. Ryoo, G.S. Falchook, R. Veillon, T. Doi, K. Yamazaki, D. Hong, S. Qin, J. Scheele, R. Bruns, K. Berghoff, S. Faivre, P.P. Paik
Journal: Annals of Oncology (2019)
A pilot study to implement an artificial intelligence (AI) system for gastrointestinal cancer clinical trial matching
Authors: Z. Jin, T. Haddad, J. Hubbard, M.L. Hartgers, K. Leventakos, K. Cornwell, K. King, B.A. Franke, K. Pomerleau, V. Bibeau, S. Coverdill, M. Rammage, J. Helgeson, A. Mahipal
Journal: Annals of Oncology (2019)
Platelet and Inflammatory Alterations Associated with Late Restenosis in Patients Undergoing Angioplasty and Brachytherapy.
Authors: Walter P. Jeske, Gary Maszak, Ravjyot Chawla, Leslie Cho, Bruce E. Lewis, Lowell H. Steen, Ferdinand Leya, Jeanine M. Walenga
Journal: Blood (2004)
Presence of circulating tumour DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis
Authors: A. Correa, D.C. Connolly, M. Balcioglu, H.-T. Wu, S. Dashner, S. Shchegrova, E. Kalashnikova, H. Pawar, R.G. Uzzo, Y. Gong, D. Kister, M. Collins, M. Donovan, R. Winters, A. Aleshin, H. Sethi, R. Salari, M. Louie, B. Zimmermann, P. Abbosh
Journal: Annals of Oncology (2019)
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
Authors: Carolyn Y. Ho, Sharlene M. Day, Euan A. Ashley, Michelle Michels, Alexandre C. Pereira, Daniel Jacoby, Allison L. Cirino, Jonathan C. Fox, Neal K. Lakdawala, James S. Ware, Colleen A. Caleshu, Adam S. Helms, Steven D. Colan, Francesca Girolami, Franco Cecchi, Christine E. Seidman, Gautam Sajeev, James Signorovitch, Eric M. Green, Iacopo Olivotto
Journal: Circulation (2018)

A better understanding of the factors that contribute to heterogeneous outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically needed to improve patient management and outcomes. The Sarcomeric Human Cardiomyopathy Registry (SHaRe) was established to provide the scale of data required to address these issues, aggregating longitudinal datasets curated by eight international HCM specialty centers.
Identification of FES as a Novel Radiosensitizing Target in Human Cancers
Authors: Byoung Hyuck Kim, Yong Joon Kim, Myung-Ho Kim, Yi Rang Na, Daun Jung, Seung Hyeok Seok, Joon Kim, Hak Jae Kim
Journal: Clinical Cancer Research (2019)

The identification of novel targets for developing synergistic drug-radiation combinations would pave the way to overcome tumor radioresistance. We conducted cell-based screening of a human kinome siRNA library to identify a radiation-specific kinase that has a synergistic toxic effect with radiation upon inhibition and is not essential for cell survival in the absence of radiation.Unbiased RNAi screening was performed by transfecting A549 cells with a human kinome siRNA library followed by irradiation. Radiosensitizing effects of a target gene and involved mechanisms were examined.We identified the nonreceptor protein tyrosine kinase FES (FEline Sarcoma oncogene) as a radiosensitizing target. The expression of FES was increased in response to irradiation. Cell viability and clonogenic survival after irradiation were significantly decreased by FES knockdown in lung and pancreatic cancer cell lines. In contrast, FES depletion alone did not significantly affect cell proliferation without irradiation. An inducible RNAi mouse xenograft model verified in vivo radiosensitizing effects. FES-depleted cells showed increased apoptosis, DNA damage, G2-M phase arrest, and mitotic catastrophe after irradiation. FES depletion promoted radiation-induced reactive oxygen species formation, which resulted in phosphorylation of S6K and MDM2. The radiosensitizing effect of FES knockdown was partially reversed by inhibition of S6K activity. Consistent with the increase in phosphorylated MDM2, an increase in nuclear p53 levels was observed, which appears to contribute increased radiosensitivity of FES-depleted cells.We uncovered that inhibition of FES could be a potential strategy for inducing radiosensitization in cancer. Our results provide the basis for developing novel radiosensitizers.